[Poseidonol in the treatment of patients with hyperlipidemia].
An antilipidemic effect of poseidonol was tested in 123 patients with ischemic heart disease, stable angina of effort (II-III functional class), 40 patients with secondary pyelonephritis and 40 patients with chronic hepatosis-hepatitis associated with chronic alcoholism or diabetes mellitus. The patients had also hyperlipidemia. A positive effect of poseidonol was established: cholesterol content fell by 25.4, 20.6 and 18.7%, respectively; triglycerides level decreased by 63, 42 and 21.4%, respectively; B-lipoproteins fell by 55.5, 36.9 and 13.1%, respectively. High density lipoproteins rose by 40.2, 27 and 69.9%, respectively. No adverse effects either on the liver or kidney functions were observed.
Panchenko
V M
VM
Isaev
V A
VA
Nalukhanian
S O
SO
Ershov
A A
AA
Zimovchenko
G S
GS
D006801:Humans; D006950:Hyperlipidemia, Familial Combined / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D007677:Kidney Function Tests; D008074:Lipoproteins / Q000378:metabolism; D008111:Liver Function Tests; D016896:Treatment Outcome
D000960:Hypolipidemic Agents; D008074:Lipoproteins
Poseĭdonol v lechenii bol'nykh s giperlipidemieĭ.